Fund to focus on its pioneering ‘asset-centric’ investment model, backing visionary biopharma entrepreneurs and drug hunters along the full drug development spectrum 27 July 2023, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces its $400 million Medicxi IV fund. The new fund will continue to support drug hunters with clear product […]
Winner of two Queen’s Awards for Enterprise in Innovation and International Trade Highest year-on-year sales growth in the company’s 25-year history Keele, UK, 14 December 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is celebrating its 25th anniversary […]
The leading European central nervous system specialty company expands its operations in the highly attractive Swiss market and introduces Jörg Gärtner as new country manager Dusseldorf and Liestal, May 3, 2022 – Neuraxpharm Group (Neuraxpharm) ignites the next level of their business in Switzerland to leverage the full potential of the important pharmaceutical market. After having […]
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Copenhagen, Denmark, May 3, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the […]
Expansion into new geographies and enhanced approval for STIMULAN to treat bacterial infection Keele, UK, 15 December 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to provide the following business update. Read more…
